Insulin C-alpha Peptides for Amyloidosis and Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes and Alzheimer's disease do not effectively address the divergence of insulin post-translational products and their functions in islets and the brain, leading to unmanaged amyloidosis and inadequate glucose regulation.
Innovation Solution
The use of newly identified human insulin isoforms and Cα peptides, including modifications such as N-terminal acetylation and PEGylation, to administer as compositions for treating diabetes and Alzheimer's disease, inhibiting amyloidosis, and detecting insulin peptide levels through mass spectrometry methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional insulin treatments are used, then glucose regulation is achieved, but amyloidosis remains unmanaged and cognitive function does not improve
Solution Approach 1:
The patent segments the insulin molecule into distinct functional components (A-chain, B-chain, and C-peptide) and separately addresses amyloidosis treatment through specific C-peptide derivatives and combination therapies, allowing simultaneous glucose regulation and amyloid management that conventional single-agent insulin cannot achieve
Solution Approach 2:
The patent develops multi-functional treatment compositions that simultaneously address diabetes (glucose regulation) and Alzheimer's disease (amyloidosis) through combination of insulin analogs, C-peptide derivatives, and adjuvant agents, enabling one treatment regimen to serve multiple therapeutic purposes
2Reliability
If standard insulin therapy is administered, then metabolic function is maintained, but cognitive impairment and amyloid deposition continue to progress
Solution Approach 1:
The patent introduces C-peptide derivatives as intermediary substances that mediate between insulin's metabolic effects and neuroprotective functions, with specific C-peptide sequences serving as active agents that inhibit amyloid deposition while maintaining glucose regulation, thereby addressing cognitive impairment without sacrificing metabolic control
3Reliability
If existing treatment protocols are used, then diabetes is managed, but amyloidosis and neurodegeneration are not addressed
Solution Approach 1:
The patent creates dynamic treatment strategies that adapt to different disease stages and patient needs, using combination therapies that can be adjusted to simultaneously manage diabetes, amyloidosis, and cognitive function, transforming static insulin therapy into a flexible, multi-targeted approach
Data Source
AI summary
Methods of treating a subject with diabetes or Alzheimer's disease with a disclosed insulin isoform or Cα polypeptide are provided. Methods of detecting insulin isoforms or Cα polypeptides are also provided.